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Introduction 
Since the launch of the Swedish Knee Arthroplasty Registry in 19751 the influence of arthroplasty 
registry research on trauma and orthopaedic surgery has expanded rapidly. Our own articles using 
registry data last year, suggested that hip and knee replacements can be expected to last over 25 
years2,3 but linked routine datasets have the potential to answer far more complex questions than 
simply implant survival. At the time of writing there are 37 members of the International Society of 
Arthroplasty Registries (ISAR)4 with the National Joint Registry for England, Wales, Northern 
Ireland and the Isle of Man (NJR) holding over three million patient records with longest follow-up 
over 15 years. Whilst a valuable resource, registry data does have its limitations,5,6 including their 
observational nature (precluding statements of causality without the use of advanced statistical 
techniques) and as such struggle to provide one single definitive answer to any research question. 
Triangulation of evidence and consistency of findings between study modalities are more likely to 
provide robust answers to important clinical questions, after all there is a known observation effect 
and difference in patients that choose to take part in clinical trials compared to those who do not. In 
the future embedding trials within routinely collected data such as registries is likely to become a 
bastion of orthopaedic research. In this, and subsequent articles we aim to draw attention to a 
selection of registry-based articles that we believe hold important messages and to highlight their 
strengths and limitations, as well as offer our own interpretation of their findings on clinical practice. 
Articles were identified through a date limited search of Medline and Embase using a mix of 
keywords and MeSH headings on Ovid SP. 
Hip 
As the available follow-up in registry studies of hip arthroplasty becomes longer, authors have turned 
their eye to increasing generalisability through collaboration. In the work from Oxford published in 
April 2019, Ferguson et al. performed a combined analysis of the Geneva and Swedish registries to 
investigate the influence of American Society of Anaesthesiologists score (ASA) on reoperation in 
Total Hip Replacement (THR) in the early post-operative period.7 They observed an adjusted Hazard 
Ratio (HR) of  all-cause revision within 3 months of the primary operation of 2.7 (95% CI 1.2, 5.9) in 
Geneva and 3.3 (95% CI 2.6, 4.0) in Sweden for patients with an ASA of III-IV compared to those 
with an ASA of I. This analysis, based on 5,319 and 122,241 THRs from Geneva and Sweden 
respectively, led them to conclude that targeted risk reduction strategies in patients with ASA III-IV 
may be appropriate. These findings were consistent with two previous studies from New Zealand and 
the Netherlands making the results more credible. As the authors point out, ASA is a subjective 
scoring system, however the “grey area” is more likely to exist between ASA I and II patients and 
there is more of a stark difference between a patient with ASA of III and above compared to one with 
an ASA of I. What interventions are available and whether they would make any difference is likely 
to be beyond the scope of observational data and offers an opportunity for future randomised studies. 
Given findings were independent of age, sex, BMI, future work to look at reasons for revision and 
potential causes is also likely warranted. 
 
With recently reported generalisable long-term survival outcomes of THR being greater than many 
expected, the group of patients most likely to be interested are those falling into the young or very 
young categories. This particular question was addressed in another collaborative article by Halvorsen 
et al. using the Nordic Arthroplasty Register Association (NARA) who analysed outcomes of 881 
THRs in patients 21 years or younger between 1995 and 2016.8 These THRs, most commonly 
implanted for paediatric hip diseases, demonstrated an unadjusted 10-year survival of 86% (95% CI 
83, 89) and 15-year survival of 73% (95% CI 68,78). After adjusting for sex, indication, head size and 
time-period of surgery the authors were unable to demonstrate any difference in survival between 
cemented and cementless implants, further putting pay to the myth that younger patients achieve 
better implant survival from cementless technology. 
Knee 
NICE guidelines (based heavily on randomised trials rather than observational data) updated in 
August of 2019 suggest 14 days of aspirin is sufficient VTE prophylaxis following TKR. This 
recommendation is supported by the recently published work of Hood et al. analysing the Michigan 
Arthroplasty Registry Collaborative Quality Initiative (MARQUI) database.9 Their study published in 
JAMA Surgery suggested that in patients undergoing TKR, treatment with aspirin alone falls within a 
30% non-inferiority margin of all other modalities of chemical thromboprophylaxis combined, for the 
outcomes of both first occurrence of VTE and death. Their cohort of nearly 42,000 patients in a US 
setting may not be news to a UK audience but is certainly of importance to those practicing TKR in 
North America. 
 
Patella resurfacing in TKR is a much-discussed subject and Maney et al. attempted to tackle this in 
their analysis of the New Zealand arthroplasty registry published in JBJS(Am) in March of 2019.10 
They aimed to answer three main questions purporting to whether a surgeon usually, selectively or 
rarely resurfaces a patella in TKR: who does what, which tactic yields the best survival and which 
gives the best Oxford Knee Score (OKS) after six months and five years? The analysis of 57,766 
primary TKRs performed between 1999 and 2015, unsurprisingly demonstrated the majority (57%) of 
surgeons had employed selective resurfacing, but more interestingly they also observed that only 7% 
appeared to “usually resurface”. There was no observed difference in overall revision rate (per 100 
component years) between groups but “usually” resurfacing appeared to offer higher OKS after both 
six months and five years. This interesting and well written analysis is however fraught with the 
challenges of selection bias, low power and sub-group analysis. The authors highlight that selective 
resurfacing is associated with lower cumulative incidence of revision in posterior stabilised TKR but 
higher in mobile bearing TKR. What this article does further emphasise is that the decision of whether 
to resurface or not should rely on a knowledge of which prosthesis is being used and its 
characteristics. The debate as to whether re-surfacing of a patella should count as a revision is not 
addressed by this study and will remain controversial in the UK, particularly amongst those that do 
not routinely resurface. 
Shoulder and Elbow 
The shoulder papers that caught our interest over the last year both came from analyses of the Nordic 
(NARA) database. The first of these articles looked at a comparison of short term (six year) survival 
between stemmed and stemless shoulder arthroplasty with the second article comparing infection rates 
between reverse shoulder replacement (RSR) and hemiarthroplasty.11,12  
 
The population in Rasmussen et al.’s article in the Journal of Shoulder and Elbow surgery12 was 
patients with osteoarthritis (OA) who underwent shoulder replacement between 2011 and 2016 in 
Denmark, Finland, Norway or Sweden. The intervention was stemless shoulder replacement and 
comparator was the more frequently implanted stemmed shoulder replacement. The outcome of 
interest was revision for any indication, defined as the removal or exchange of any component. This 
cohort study was analysed using Cox proportional hazards modelling with age, sex, previous surgery 
and time period as co-variates. The authors report no evidence against the null hypothesis that 
survival between the two groups is the same after six years (HR 1.00 95% CI 0.63, 1.61), however 
these results should be interpreted with caution. The main reason for this is the inherent selection bias 
in determination of type of implant to be used. There were differences in the age and sex distribution 
between groups and whilst a Cox model attempts to control for this, it cannot control for selection 
bias (a systematic difference between groups). The authors also explain that they did not differentiate 
between implant brand (which may have an influence on survival) and that the choice of a stemless 
implant is reliant on bone stock, which reduces the generalisability of the study because not all 
patients could feasibly have received either intervention. We suggest therefore that the jury is still out 
regarding equivalence of these two systems and we should wait for further evidence.  
 
The second article authored by Moeini et al.11 in the Bone and Joint Journal was an analysis of nearly 
18,000 shoulders looking at the risk of revision for infection in RSR compared to anatomical TSR or 
hemiarthroplasty. The population was all patients undergoing replacement within the NARA dataset 
between 2004 and 2013 with the outcome revision due to infection (defined as removal or exchange 
of any part of the primary arthroplasty or the addition of a glenoid component to an existing 
hemiarthroplasty and infection based on “preoperative assessment and perioperative findings”). The 
authors report increased risk of revision due to infection in RSR compared to anatomical shoulder 
replacement in both the crude model and the adjusted model for age, sex, indication and year of 
surgery. The observed effect was greatest in men and younger patients. This analysis is again affected 
by selection bias as the authors themselves observed that rotator-cuff deficiency is a predictor of 
revision for infection. This article is certainly food for thought, but with RSR being the bail out option 
in many patients rather than a choice, implementation of the findings may be variable. Further work 
on why cuff deficient shoulder are at risk of infection following arthroplasty is certainly warranted. 
 
Registry findings on total elbow arthroplasty (TEA) have, like ankle arthroplasty, been limited by the 
relatively low numbers. The size of the datasets in comparison to centre case series however is one of 
the strengths of registries, and further work will arise to give us clues to the future direction of travel 
in research questions. In their article published in Acta Orthopaedica in August 2019, Viveen et al. 
reported on 1200 primary total elbow replacements from the Australian Orthopaedic Association 
National Arthroplasty Replacement Registry (AOANARR) implanted between 2008 and 2018.13 They 
observed an almost equal three way split for indication of TEA between trauma, osteoarthritis (OA) 
and rheumatoid arthritis (RA) overall, but in more recent times (since 2016) trauma and OA are 
becoming more common whilst RA is decreasing in frequency, likely due to the improved medical 
management of RA. TEA performed for OA appeared to show a higher revision rate compared to 
trauma (HR 1.8 95% CI 1.1, 3.0) and RA (HR 2.0 95% CI 1.3, 3.1). Across all cases, the most 
common reasons for revision were infection (35%) and aseptic loosening (34%); overall unadjusted 
cumulative percentage revision was 10%, 15% and 19% at three, five and nine years respectively. The 
authors note that they did not observe any difference in revision estimates between different 
prostheses. The take home message from this article is the difference in revision estimates between 
indications, but as the authors note these are only survival analyses and no PROMs could be included, 
they were also unable to tell whether TEAs implanted for trauma were performed acutely or as 
salvage procedures. 
Foot and ankle 
To date, registry survival studies on total ankle replacement (TAR) have been somewhat limited by 
the numbers implanted and this year’s joint RCS(Eng)/NJR research fellowship was awarded to a 
trainee intent on overcoming this problem. In their systematic review published in Orthopaedic 
Clinics of North America, Jeyaeelan et al. attempted to draw a useful line in the sand as to what the 
registry data tells us to date.14 Using data up to 2017, the authors compiled 11,567 TARs from the 
registries of Sweden, Norway, New Zealand, Australia and the UK, with the UK providing the 
greatest number with 4,687. Five-year survival ranged from 89.6% to 93.1% across these registries 
with 10-year survival of 69% and 82.8% reported by the Swedish and New Zealand registries 
respectively. The authors note a 2013 meta-analysis of case-series by Goldberg et al. reporting an 
89% 10-year survival, however given the over-estimate of survival in case-series for THR and TKR in 
our recent articles2,3 we would recommend taking more attention of registry data compared to case-
series subject to reporting bias. The main limitation of any study using registry data to analyse TAR is 
the small numbers seen within subgroups of particular implants leading to a reduction in power to 
detect a difference in survival, particularly given a sample size of at least 1600 in each group is 
recommended.15 This means that whilst the figures summarising survival in TAR are interesting they 
provide little information to patients considering operation now. 
Conclusion 
2019 has proven to be an interesting year for registry research. As the ability and willingness to 
collaborate between registries increases, we are likely to see larger and more generalisable studies. 
Some of the challenges with collaborative work, such as implant identification codes and sharing of 
pseudo-individualised patient level data are being addressed by the ISAR and we look forward to the 
results of this work as well as more interesting articles coming from registries around the world. 
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